t
ECO Animal Health Group plc announced on 29 August 2024 that on 28 August 2024, it granted nominal cost share options over 143,452 ordinary shares to two Executive Directors, David Hallas (CEO) and Chris Wilks (CFO). These options, representing approximately 0.21 percent of the Company's issued share capital, were awarded at 5p each as a deferral of 33% of their annual bonus for the financial year ended 31 March 2024, with Hallas receiving 82,437 and Wilks 61,015.
| Date | 29 Aug 2024 |
| Time | 07:00:11 |
| Category | Director/PDMR dealings |
| ID | 0512C |
29 August 2024
ECO Animal Health Group plc
("ECO" or the "Company")
Deferred Share Option Awards to Executive Directors
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that on 28 August 2024 nominal cost share options were granted under the Company's Deferred Bonus Plan ("DBS") over 143,452 ordinary shares in the Company (representing approximately 0.21 percent of the Company's issued share capital) to two Executive Directors listed below. These awards relate to the deferral of 33% of the annual bonus for Executive Directors earned in respect of the Company's financial year ended 31 March 2024.
|
Name |
Position |
Number of Deferred Share Options |
|
David Hallas |
Chief Executive Officer |
82,437 |
|
Chris Wilks |
Chief Financial Officer |
61,015 |
As indicated in the Circular to shareholders dated 4 February 2021, the DBS has been established to allow the Remuneration Committee to require a significant part of the annual bonuses paid to Executive Directors to be deferred in exchange for an award of nominal cost options which vest after 3 years.
-Ends-
For further information please contact:
|
|
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.
Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com
PDMR Notification - ECO DBS Deferred Share Option Awards
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||
|
a. |
Name |
1. David Hallas 2. Chris Wilks
|
||||||
|
2. |
Reason for the notification |
|||||||
|
a. |
Position/status |
1. Chief Executive Officer 2. Chief Financial Officer
|
||||||
|
b. |
Initial notification /Amendment |
Initial notification |
||||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||
|
a. |
Name |
Eco Animal Health Group Plc |
||||||
|
b. |
LEI |
2138009XN9DJ3YP70B55 |
||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a. |
Description of the Financial instrument, type of instrument Identification code |
Options over ordinary shares of 5p each.
GB0032036807
|
||||||
|
b. |
Nature of the transaction |
Award of nominal cost share options under the Company's DBS. |
||||||
|
c. |
Price(s) and volume(s) |
Numbers 1 and 2 in the left-hand column correspond to the relevant PDMR as detailed in boxes 1a and 2a above.
|
||||||
|
d. |
Aggregated information Aggregated volume Price
|
n/a
|
||||||
|
e. |
Date of the transaction |
28 August 2024 |
||||||
|
f. |
Place of the transaction |
Outside a trading venue.
|
||||||